Clinical trials: Albuminuria
Diabetic Kidney Disease, Type2 Diabetes
Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.
Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide.
- Trial name
- NCT04176276
- Testing
- no interventions required.
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pisa
Type 2 Diabetes Mellitus With Kidney Complications
The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia
To investigate whether concomitant treatment with Lokelma can improve the efficacy of standard blockade of the renin-angiotensin system in patients with type 2 diabetes, diabetic nephropathy and hyperkalemia.
- Trial name
- ZIRCUS (NCT04063930)
- Testing
- LOKELMA 5 GM Powder for Oral Suspension
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Steno Diabetes Center Copenhagen
Microalbuminuria, Proteinuria
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
This study is designed to assess the efficacy of the different dosage forms of Valsartan[80, 160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.
- Trial name
- NCT00550095
- Testing
- valsartan
- Where
- Egypt
- Volunteers
- 509 people
- Sponsor
- Novartis
Albuminuria
Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Phosphorus-based food additives are commonly used by food manufacturers for many applications, such as enhancing flavor, in ready-to-eat foods and beverages.
- Trial name
- SODA-POP (NCT02020785)
- Testing
- Higher phosphorus period, Lower phosphorus period
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Geisinger Clinic
Diabetic Nephropathy
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline.
- Trial name
- NCT07598864
- Testing
- Dapagliflozin +Finerenone arm, Dapagliflozin arm
- Where
- Bangladesh
- Volunteers
- 88 people
- Sponsor
- Chittagong Medical College
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Chronic Kidney Disease
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with…
- Conditions
- Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
- Trial name
- NCT00552409
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Chronic Kidney Diseases, Albuminuria
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other…
- Conditions
- Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies
- Trial name
- PRIMETIME2 (NCT04916132)
- Testing
- Kidney Biopsy
- Where
- 13 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Herlev Hospital
Type 2 Diabetes Mellitus
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
The primary purpose of this study is to assess the renal protective effect of ipragliflozin in combination with metformin on the percent change of UACR from baseline to 24 weeks against glimepiride in combination with metformin…
- Trial name
- NCT03118713
- Testing
- metformin, ipragliflozin, glimepiride
- Where
- 8 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Astellas Pharma Korea, Inc.
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Diabetic Nephropathy, Albuminuria
Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients
Current therapies targeting albuminuria in diabetic nephropathy leave residual urinary albumin secretion, which meanwhile leave residual cardiovascular risk.
- Trial name
- Soften (NCT01316068)
- Testing
- intravenous use of sulodexide followed by oral use, use of sulodexide orally only
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Focal Segmental Glomerulosclerosis
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk factor for end stage renal failure.
- Trial name
- TRANSLATE (NCT02585804)
- Testing
- Dapagliflozin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes, Diabetic Nephropathy
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
Diabetic kidney disease has become the leading cause for ESRD worldwide.Albuminuria is a major risk factor for progression of diabetic nephropathy.
- Trial name
- NCT04127084
- Testing
- SGLT2 Inhibition
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhongshan Hospital Xiamen University
Lupus Nephritis (LN), ANCA Associated Vasculitis (AAV)
SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis
The goal of this clinical trial is to investigate the effect of the glifozines on albuminuria in chronic kidney disease patients affected by lupus nephritis and ANCA associated renal vasculitis.
- Trial name
- NCT07035834
- Testing
- Gliflozin
- Volunteers
- 40 people
- Sponsor
- Federico II University
CKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes…
- Trial name
- NCT07719621
- Where
- Spain
- Volunteers
- 100,000 people
- Sponsor
- Aeterna Medical Solutions SL
Diabetic Nephropathy
Eplerenone, ACE Inhibition and Albuminuria
The purpose of this study is to determine whether eplerenone is more effective than doubling the dose of ACE inhibitor in reducing urinary protein (albumin) loss in diabetes mellitus
- Trial name
- NCT00315016
- Testing
- eplerenone, fosinopril
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes Mellitus, Cardiovascular Disease
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to…
- Trial name
- ALTITUDE (NCT00549757)
- Testing
- Aliskiren
- Where
- 776 sites in United States, Argentina and 35 more
- Volunteers
- 8,606 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Diabetic Nephropathy
The Effects of Bindarit in Diabetic Nephropathy
The purpose of this study is to determine whether bindarit is effective to reduce albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a background therapy.
- Trial name
- NCT01109212
- Testing
- Bindarit
- Where
- 6 sites in Italy, Slovenia
- Volunteers
- 100 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Diabetes Mellitus, Type I, Diabetic Nephropathy
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy.
- Trial name
- NCT00118976
- Testing
- Lisinopril
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steno Diabetes Center Copenhagen